cMet is deregulated in many types of human malignancies and this has been correlated with poor clinical outcome; cMet remains an attractive drug target in oncology with many small molecule and biologic programs currently underway.

This white paper presents a comprehensive scientific overview of the cMet pathway and drugs under clinical development integrated with operational considerations on how to manage clinical trials in this indication.